Skip to main content
logo
Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,343,000
-43,000 (-3.10%)
At close: Jun 26, 2026

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Domestic Revenue
371.88B558.09B
Domestic Revenue Growth
-33.37%387.12%
Europe Revenue
2.37T2.04T
Europe Revenue Growth
16.31%-13.51%
USA Revenue
1.73T822.63B
USA Revenue Growth
110.78%-15.29%
Other Geographic Revenue
83.43B80.66B
Other Geographic Revenue Growth
3.44%-68.38%

Revenue Breakdown

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Contract Development and Manufacturing Organization (CDMO) Revenue
4.56T3.50T
Contract Development and Manufacturing Organization (CDMO) Revenue Growth
30.30%30.77%
Biopharmaceutical Development and Commercialization Revenue
-1.54T
Biopharmaceutical Development and Commercialization Revenue Growth
-50.71%

Revenue Breakdown 2

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Product Revenue
4.36T3.38T
Product Revenue Growth
28.93%-0.66%
Other Revenue
198.72B116.72B
Other Revenue Growth
70.26%-59.98%

EBIT

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Contract Development and Manufacturing Organization (CDMO) Operating Profit
2.07T1.32T
Contract Development and Manufacturing Organization (CDMO) Operating Profit Growth
56.60%21.43%
Biopharmaceutical Development and Commercialization Operating Profit
-200.69B
Biopharmaceutical Development and Commercialization Operating Profit Growth
-688.24%